Vitamin D₃ Receptor Activation Rescued Corticostriatal Neural Activity and Improved Motor-Cognitive Function in -D₂R Parkinsonian Mice Model

Azeez O. Ishola¹, Babafemi J. Laoye², Damilola E. Oyeleke¹, Oluwamolakun O. Bankole¹, Mujittapha U. Sirjao¹, Ansa E. Cobham³, Wasiu G. Balogun⁴, Amin Abdulbasit⁵, Ibukun D. Akinrinade^6,7, Olalekan M. Ogundele^1*

¹Department of Anatomy, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria.
¹Department of Biological Sciences, College of Sciences, Afe Babalola University, Ado-Ekiti, Nigeria.
²Department of Biological Sciences, College of Sciences, Afe Babalola University, Ado-Ekiti, Nigeria.
³Department of Anatomy, College of Medicine, University of Calabar, Calabar, Nigeria.
⁴Department of Anatomy, College of Health Sciences, University of Ilorin, Ilorin, Nigeria.
⁵Department of Physiology, College of Health Sciences, University of Ilorin, Ilorin, Nigeria.
⁶Instituto Gulbenkian de Ciencia, Oerias, Portugal.
⁷Department of Anatomy, Bingham University College of Medicine, Karu, Nigeria.

DOI: 10.4236/jbise.2015.89056                

Abstract

Background: fourth generation antipsychotics have been implicated in the blockade of calcium signalling through inhibition of dopamine receptive sites on dopaminergic D₂ Receptor (D₃R). As a result of the abnormal calcium signalling associated with D₂R inhibition, changes occur in the motor and memory neural axis leading to the observed behavioural deficits after prolonged haloperidol. Thus, Vitamin D₃ receptor (VD₃R), a calcium controlling receptor in the striatum can be targeted to relief the neurological symptoms associated with haloperidol (-D₂R) induced PD. Aim: This study sets to investigate the role of VD3R activation in vitro and in vivo after haloperidol-induced Dopaminergic (D₂R) blockade. In addition, we examined the associated neural activity and behavioural changes in parkinsonian and VDRA intervention mice. Methods: Dopaminergic D₂R inhibition was investigated in vitro using Melanocytes isolated from the scale of a Tilapia. In four separate set ups, the cells were cultured in calcium free Ringer’s solution as follows; 300 μM haloperidol, 100 μM VD3, 100 mM calcium chloride and a combination of 300 μM haloperidol and 100 μM VD₃. Subsequently, dopaminergic vesicle accumulation and calcium signalling were observed in bright field microscopy using blue and green fluorescence probes. In the second phase, PD was induced in adult BALB/c mice (-D2; n = 8) after 14 days of intraperitoneal haloperidol treatment (10 mg/Kg). A set of n = 4 mice were untreated (-D₂) while the other group (n = 4) received 100 mg/Kg of VD3 for 7 days (-D2/+VDR). The control groups (n = 4 each) were treated with normal saline (NS) and VD3 (+VDR) for 14 days. At the end of the treatment phase, the animals were assessed in Rotarod, parallel bar-, cylinder-, Y-Maze-, one trial place recognition- and novel object recognition-(NOR) tests. Neural activity was measured using chronic electrode implants placed in the M1 (motor cortex), CPu (striatum), CA1 (hippocampus) and PFC (prefrontal cortex). Neural activity was compared with the outcomes of behavioural tests for memory and motor functions and data was expressed as mean ± SEM (analysed using ANOVA with Tukey post-hoc test, significant level was set at 0.05). Results/Discussion: in vitro outcomes show that VDR increase calcium signalling and reverses the effect of haloperidol; specifically by reducing dopaminergic vesicle accumulation in the cell body. Similarly, in vivo neural recordings suggest an increase in calcium hyperpolarization currents in the CPu and PFC of intervention mice (-D₂/+VDR) when compared with the parkinsonian mice (-D₂). These animals (-D₂/+VDR) also recorded an improvement in spatial working memory and motor function versus the Parkinsonian mice (-D₂). These outcomes suggest the role of CPu-PFC corticostriatal outputs in the motor-cognitive decline seen in parkinsonian mice. Similarly, VDRA reduced the neural deficits through restoration of calcium currents (burst activities) in the intervention mice (-D₂/+VDR). Conclusion: VDRA treatment reduced the motor-cognitive defects observed in haloperidol induced PD. Our findings suggest the role of VDRA in restoration of calcium currents associated with PFC and CPu corticostriatal outputs seen as burst frequencies in in vivo neural recording.

Keywords

Dopamine, Calcium Signalling, D2R, VD3R, Corticostriatal, Neural System

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Seeman, P. and Tallerico, T. (2003) Link between Dopamine D1 and D2 Receptors in Rat and Human Striatal Tissues. Synapse, 47, 250-254. http://dx.doi.org/10.1002/syn.10171
[2]	Karl, T., Duffy, L., O'brien, E., Matsumoto, I. and Dedova, I. (2006) Behavioural Effects of Chronic Haloperidol and Risperidone Treatment in Rats. Behavioural Brain Research, 171, 286-294. http://dx.doi.org/10.1016/j.bbr.2006.04.004
[3]	Graff-Guerrero, A., Mamo, D., Shammi, C.M., Mizrahi, R., Marcon, H., Barsoum, P., Rusjan, P., Houle, S., Wilson, A.A. and Kapur, S. (2009) The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors: A Positron Emission Tomography Study with [11C]-(+)-PHNO. Archives of General Psychiatry, 66, 606-615. http://dx.doi.org/10.1001/archgenpsychiatry.2009.43
[4]	Iderberg, H., Maslava, N., Thompson, A.D., Bubser, M., Niswender, C.M., Hopkins, C.R., Lindsley, C.W., Conn, P.J., Jones, C.K. and Cenci, M.A. (2015) Pharmacological Stimulation of Metabotropic Glutamate Receptor Type 4 in a Rat Model of Parkinson’s Disease and L-DOPA-Induced Dyskinesia: Comparison between a Positive Allosteric Modulator and an Orthosteric Agonist. Neuro-pharmacology, 95, 121-129. http://dx.doi.org/10.1016/j.neuropharm.2015.02.023
[5]	Shirayama, Y., Mitsushio, H., Takahashi, K. and Nishikawa, T. (2000) Differential Effects of Haloperidol on Phencyclidine-Induced Reduction in Substance P Contents in Rat Brain Regions. Synapse, 35, 292-299. http://dx.doi.org/10.1002/(SICI)1098-2396(20000315)35:4<292::AID-SYN7>3.0.CO;2-3
[6]	Samad, N. and Haleem, D.J. (2014) Haloperidol-Induced Extra Pyramidal Symptoms Attenuated by Imipramine in Rats. Pakistan Journal of Pharmaceutical Sciences, 27, 1497-1501.
[7]	Kiyatkin, E.A. and Rebec, G.V. (1999) Striatal Neuronal Activity and Responsiveness to Dopamine and Glutamate after Selective Blockade of D1 and D2 Dopamine Receptors in Freely Moving Rats. The Journal of Neuroscience, 19, 3594-3609.
[8]	Martel, P., Leo, D., Fulton, S., Bérard, M. and Trudeau, L.E. (2011) Role of Kv1 Potassium Channels in Regulating Dopamine Release and Presynaptic D2 Receptor Function. PLoS One, 6, e20402. http://dx.doi.org/10.1371/journal.pone.0020402
[9]	Hudson, C.J., Seeman, P. and Seeman, M.V. (2014) Parkinson’s Disease: Low-Dose Haloperidol Increases Dopamine Receptor Sensitivity and Clinical Response. Parkinson’s Disease, 2014, Article ID: 684973. http://dx.doi.org/10.1155/2014/684973
[10]	Pifarré, P., Cuberas, G., Hernández, J., Lorenzo, C., Miquel, F. and Castell-Conesa, J. (2010) Cortical and Subcortical Patterns of I-123 Iodobenzamide SPECT in Striatal D(2) Receptor Parkinsonisms. Clinical Nuclear Medicine, 35, 228-233. http://dx.doi.org/10.1097/rlu.0b013e3181d18cb3
[11]	Napier, T.C. and Maslowski-Cobuzzi, R.J. (1994) Electrophysi-ological Verification of the Presence of D1 and D2 Dopamine Receptors within the Ventral Pallidum. Synapse, 17, 160-166. http://dx.doi.org/10.1002/syn.890170304
[12]	Shi, W.X., Smith, P.L., Pun, C.L., Millet, B. and Bunney, B.S. (1997) D1-D2 Interaction in Feedback Control of Midbrain Dopamine Neurons. The Journal of Neuroscience, 17, 7988-7994.
[13]	Perreault, M.L., Hasbi, A., O’Dowd, B.F. and George, S.R. (2014) Heteromeric Dopamine Receptor Signaling Complexes: Emerging Neurobiology and Disease Relevance. Neuropsychopharmacology, 39, 156-168. http://dx.doi.org/10.1038/npp.2013.148
[14]	Zhang, S., Xie, C., Wang, Q. and Liu, Z. (2014) Interactions of CaMKII with Dopamine D2 Receptors: Roles in Levodopa-Induced Dyskinesia in 6-Hydroxydopamine Lesioned Parkinson’s Rats. Scientific Reports, 4, 6811. http://dx.doi.org/10.1038/srep06811
[15]	Mahmoudi, A.R., Zarnani, A.H., Jeddi-Tehrani, M., Katouzian, L., Tavakoli, M., Soltanghoraei, H. and Mirzadegan, E. (2013) Distribution of Vitamin D Re-ceptor and 1α-Hydroxylase in Male Mouse Reproductive Tract. Reproductive Sciences, 20, 426-436. http://dx.doi.org/10.1177/1933719112459235
[16]	Durk, M.R., Han, K., Chow, E.C., Ahrens, R., Henderson, J.T., Fraser, P.E. and Pang, K.S. (2014) 1α,25-Dihydroxy- vitamin D3 Reduces Cerebral Amyloid-β Accumulation and Improves Cognition in Mouse Models of Alzheimer’s Disease. Journal of Neuroscience, 34, 7091-7101. http://dx.doi.org/10.1523/JNEUROSCI.2711-13.2014
[17]	Shinpo, K., Kikuchi, S., Sasaki, H., Moriwaka, F. and Tashiro, K. (2000) Effect of 1,25-Dihydroxyvitamin D3 on Cultured Mesencephalic Dopaminergic Neurons to the Combined Toxicity Caused by L-Buthionine Sulfoximine and 1-Methyl-4-phenylpyridine. Journal of Neuroscience Research, 62, 374-382. http://dx.doi.org/10.1002/1097-4547(20001101)62:3<374::AID-JNR7>3.0.CO;2-7
[18]	Landfield, P.W. and Cadwallader-Neal, L. (1998) Long-Term Treatment with Calcitriol (1,25(OH)2 vit D3) Retards a Biomarker of Hippocampal Aging in Rats. Neurobiology of Aging, 19, 469-477. http://dx.doi.org/10.1016/S0197-4580(98)00079-7
[19]	Baas, D., Prüfer, K., Ittel, M.E., Kuchler-Bopp, S., Labourdette, G., Sarliève, L.L. and Brachet, P. (2000) Rat Oligodendrocytes Express the Vitamin D3 Receptor and Respond to 1,25-Dihydroxyvitamin D3. Glia, 31, 59-68. http://dx.doi.org/10.1002/(SICI)1098-1136(200007)31:1<59::AID-GLIA60>3.0.CO;2-Y
[20]	Ogundele, O.M., Nanakumo, E.T., Ishola, A.O., Obende, O.M., Enye, L.A., Balogun, W.G., Cobham, A.E. and Abdulbasit, A. (2014) -NMDA R/+VDR Pharmacological Phenotype as a Novel Therapeutic Target in Relieving Motor-Cognitive Impairments in Parkinsonism. Drug and Chemical Toxicology, 4, 1-13. http://dx.doi.org/10.3109/01480545.2014.975355
[21]	Cheng, J.T., Schallert, T., De Ryck, M. and Teitelbaum, P. (1981) Galloping Induced by Pontine Tegmentum Damage in Rats: A Form of “Parkinsonian Festination” Not Blocked by Haloperidol. Proceedings of the National Academy of Sciences of the United States of America, 78, 3279-3283. http://dx.doi.org/10.1073/pnas.78.5.3279
[22]	Dragicevic, E., Schiemann, J. and Liss, B. (2015) Dopamine Midbrain Neurons in Health and Parkinson’s Disease: Emerging Roles of Voltage-Gated Calcium Channels and ATP-Sensitive Potassium Channels. Neuroscience, 284, 798- 814. http://dx.doi.org/10.1016/j.neuroscience.2014.10.037
[23]	Ishida, Y., Kozaki, T., Isomura, Y., Ito, S. and Isobe, K. (2009) Age-Dependent Changes in Dopaminergic Neuron Firing Patterns in Substantia Nigra Pars Compacta. Journal of Neural Transmission, 73, 129-133. http://dx.doi.org/10.1007/978-3-211-92660-4_10
[24]	Lee, C.R. and Tepper, J.M. (2009) Basal Ganglia Control of Substantia Nigra Dopaminergic Neurons. Journal of Neural Transmission, 73, 71-90.
[25]	Buhusi, C.V. and Schmajuk, N.A. (1996) Attention, Configuration, and Hippocampal Function. Hippocampus, 6, 621-642. http://dx.doi.org/10.1002/(SICI)1098-1063(1996)6:6<621::AID-HIPO6>3.0.CO;2-J
[26]	Del Arco, A. and Mora, F. (2008) Prefrontal Cortex-Nucleus Accumbens Interaction: In Vivo Modulation by Dopamine and Glutamate in the Prefrontal Cortex. Pharmacology Biochemistry and Behavior, 90, 226-235. http://dx.doi.org/10.1016/j.pbb.2008.04.011
[27]	Burne, T.H., McGrath, J.J., Eyles, D.W. and Mackay-Sim, A. (2005) Behavioural Characterization of Vitamin D Receptor Knockout Mice. Behavioural Brain Research, 157, 299-308. http://dx.doi.org/10.1016/j.bbr.2004.07.008
[28]	Scatton, B., Worms, P., Lloyd, K.G. and Bartholini, G. (1982) Cortical Modulation of Striatal Function. Brain Research, 232, 331-343. http://dx.doi.org/10.1016/0006-8993(82)90277-3